ADMA Biologics, Inc. Reports 2012 Year End Financial and Operational Results  
3/7/2013 6:19:51 AM

ADMA Biologics, Inc. (ADMA), a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases, today reported financial and operational results for the year ended December 31, 2012. Year-end and subsequent highlights include:

•Secured $6 million term loan to advance Phase III study
• Executed long-term manufacturing, supply and license agreement for RI-002